Highest risk CLL patients may benefit from CAR T with BTK inhibitor [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Johnson & Johnson's (J&J's) Imbruvica (ibrutinib) for relapsed/refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) were presented at the American Society of Hematology (ASH) annual meeting held from 7 December to 10 December 2024 in San Diego, California. The study protocol requires patients to take ibrutinib for varying lengths of time before undergoing leukapheresis. They may continue to take ibrutinib after chimeric antigen receptor (CAR) T cell infusion. At the January 2024 data cutoff, 50% of enrolled patients had completed or were currently participating in the study. The objective response rate was 86%, with a median duration of response of 41.4 months. A total of 45% of the patients achieved complete remission. Secondary endpoints included a median progression-free survival of 31.4 months, but no median overall survival was reached. The regimen was well tolerated, with 86% of patients experiencing a grade =3 treatment-related adverse event (T
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Model N Achieves ISO/IEC 27001 Certification, the Global Standard for Information Security [Yahoo! Finance]Yahoo! Finance
- Why Is Johnson & Johnson (JNJ) Among the Best Dividend Stocks to Invest In? [Yahoo! Finance]Yahoo! Finance
- Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA [Yahoo! Finance]Yahoo! Finance
- Why Long-Form Entertainment Can Be A Content Marketer’s Biggest Gift: USPS’s Dear Santa Franchise [Forbes]Forbes
- Innovating With Purpose: Johnson & Johnson’s Mission To Develop Targeted Treatments For Autoantibody Diseases [Forbes]Forbes
JNJ
Earnings
- 10/15/24 - Beat
JNJ
Sec Filings
- 12/12/24 - Form 4
- 12/12/24 - Form 4
- 12/12/24 - Form 4
- JNJ's page on the SEC website